Email updates

Keep up to date with the latest news and content from BMC Surgery and BioMed Central.

Open Access Highly Accessed Case report

Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic

Eugene Sherry1*, Harry Boeck2 and Patrick H Warnke3

Author Affiliations

1 OR Design Unit, University of Sydney, Nepean Hospital, PO Box 63, Penrith NSW 2750, Australia

2 Eucanol Pty Ltd, Wollongong, NSW, Australia

3 University of Kiel, Germany

For all author emails, please log on.

BMC Surgery 2001, 1:1  doi:10.1186/1471-2482-1-1

Published: 16 May 2001

Abstract

Background

Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE, are an increasing problem world-wide, causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations in solution, ointment and cream form.

Methods

We report the first use of this drug, administered percutaneously, via calcium sulphate pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an adult male.

Results and Discussion

Over a three month period his symptoms resolved with a healing response on x-ray and with a reduced CRP.